Shots:
- Stoke Therapeutics & Biogen have dosed their first patient with zorevunersen in global P-III (EMPEROR) trial for the treatment of Dravet syndrome; Trial has initiated in the US, UK, & Japan, with an EU study planned
- Trial will assess zorevunersen (70mg on Day 1 & Wk. 8, then 45mg at Wks. 24 & 40) vs sham in Dravet syndrome pts (2–18yrs.) with confirmed SCN1A variants not linked with gain of function; pts could then enter an OLE study
- Trial will evaluate change in major motor seizure frequency at Wk. 28 as the 1EP, with 2EPs incl. change in seizure frequency, plus change in behavior & cognition per Vineland-3 subdomains at Wk. 52
Ref: Stoke Therapeutics| Image: Stoke Therapeutics and Biogen | Press Release
Related News:- Biogen’s Zurzuvae Receives the CHMP’s Positive Opinion to Treat Severe Postpartum Depression
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
